USPTO serial 87736055
CELLINK X
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 15, 2020
- Examiner
- BUTTON, JENNIFER JO
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with CELLINK X?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Margarita Wallach
Margarita Wallach McCarter & English, LLP825 Eighth Avenue, 31st FloorWorldwide PlazaNew York, NY 10019Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biologically compatible polymers, namely, hydrogels used to manufacture polymeric networks used in the manufacture of engineered living tissue for medical, scientific and non-scientific purposes; Media for cell culture for use in the biotechnological industry; Media for cell culture for use in non-medical research laboratories; Biological preparation for use in cell cultures other than for medical or veterinary use; Engineered biological tissues and tissue arrays, namely, human and animal organ, connective, epithelial, muscular, and nervous tissues and tissue arrays, for use in scientific and medical research; Biologically compatible materials, namely, hydrogels used to create polymeric networks used in the manufacture of living tissue; Proteins in raw material form for scientific and medical research | ACTIVE | — |
| 005 | Pharmaceutical preparations for use in the field of 3D bio-printing of tissues and organs; Preparations based on cellulous nano-fibrils for use in the 3D bio-printing of tissues and organs; Tissue-regenerative pharmaceutical preparations; Cells for medical use; Human allograft tissue; Living cells for medical use; Implants of living tissues for guided tissue regeneration; Implants comprising living tissue; Implantable materials of living tissue for use in guided tissue regeneration; Skin grafts; Surgical implants comprised of living tissues; Surgical implants of living tissues grown from stem cells; Transdermal patches for use to create skin for prosthetic limbs and for skin grafts; Living tissues for transplant; Engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, connective, epithelial, muscular, and nervous tissue and organs, for medical purposes; Biological molecules to assist in the development of tissue; Haemostatic gel matrix preparations for treating wounds; Natural biomaterials for augmentation of bone, blood and tissue for medical purposes; Pharmaceutical products for tissue regeneration, for tissue repair, for tissue treatment, whether relating to human or animal tissue; Pharmaceutical preparations for the treatment of bone diseases, for cartilaginous diseases, for vascular diseases, for neuronal degeneration, for degeneration of tendons and ligaments, for retinal degeneration, for renal degeneration, degeneration of soft tissue, for diseases with abnormal cell proliferation; Natural biomaterials for bone filling; Natural biomaterials for filling cartilage; Biological tissue cultures for medical use; Biological tissue cultures for medical purposes; Biological tissue grafts; Biological bone and skin tissues impregnated with lines of oxygen for tissue engineering applications to increase cell survival in tissue intended for subsequent implantation; Gene therapy products, namely, genetically engineered tissues for transplant purposes; Implantable scaffolds comprising living tissue for maintaining tissue contour; Implants comprising living tissue; Natural biomaterials for augmentation of bone and tissue for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cellink AB
- Other trademarks owned by Cellink AB
- Other trademarks owned by CELLINK BIOPRINTING AB
- Other trademarks owned by Cellink AB
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named CELLINK X
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 15, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Feb 15, 2023 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Dec 15, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 9, 2020 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Nov 9, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 8, 2020 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Oct 8, 2020 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Jul 27, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 27, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 27, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 27, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 27, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 14, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 19, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 19, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 29, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 16, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 14, 2020 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Jul 8, 2019 | GEA1 | NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED | — |
| Jul 8, 2019 | GECD | ACTION DENYING REQ FOR RECON E-MAILED | — |
| Jul 8, 2019 | CNCF | ACTION CONTINUING FINAL - COMPLETED | — |
| Jun 5, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 5, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 29, 2019 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| May 29, 2019 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| May 29, 2019 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| May 28, 2019 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Nov 28, 2018 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 28, 2018 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 28, 2018 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 29, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 29, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 18, 2018 | ALIE | ASSIGNED TO LIE | — |
| Oct 9, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 9, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 9, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 9, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 9, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 6, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 12, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 30, 2017 | NWAP | NEW APPLICATION ENTERED | — |